Please login to the form below

Not currently logged in
Email:
Password:

Tredaptive authorised in the EU

New cholesterol-lowering drug, Tredaptive, has been given marketing authorisation for use in all 27-member countries of the European Union, as well as Iceland and Norway
New cholesterol-lowering drug, Tredaptive, has been given marketing authorisation for use in all 27-member countries of the European Union, as well as Iceland and Norway.

The Merck Sharp & Dhome (MSD) manufactured medicine has been developed for the treatment of patients with dyslipidaemia, which can be a side effect of diabetes, and raised cholesterol. It has been licensed for use in combination with statins or as a monotherapy when statins are inappropriate.

According to MSD, non-pharmacological, dietary remedies such as exercise and weight reduction should be continued while patients are being treated with the medicine.

Professor Ian Young, consultant in clinical biochemistry at Queen's University in Belfast called the new drug 'an important treatment option'.

"The approval of Tredaptive in the European Union further reinforces our long-standing commitment to the cardiovascular area by bringing novel and innovative therapies to patients," said Stefan Oschmann, president of MSD Europe, Middle East, Africa and Canada.

22nd July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics